Free Trial

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's Why

Ascentage Pharma Group International logo with Medical background

Shares of Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $20.95, but opened at $18.41. Ascentage Pharma Group International shares last traded at $18.11, with a volume of 6,095 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. began coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 27th. They issued an "overweight" rating on the stock.

Get Our Latest Report on Ascentage Pharma Group International

Ascentage Pharma Group International Stock Performance

The stock has a 50-day simple moving average of $19.53.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Read More

Should You Invest $1,000 in Ascentage Pharma Group International Right Now?

Before you consider Ascentage Pharma Group International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.

While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

7 Cybersecurity Stocks Outperforming the Market Right Now
Markets in Rally Mode: Will Earnings Keep It Going?
3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines